Format

Send to

Choose Destination
Clin Chest Med. 2004 Dec;25(4):759-72, vii.

Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects.

Author information

1
Interstitial Lung Disease Program, National Jewish Medical and Research Center, Denver, CO, USA. brownk@njc.org

Abstract

A diagnosis of idiopathic pulmonary fibrosis (IPF) carries a poor prognosis, with our currently available therapies offering little clinical benefit. Unfortunately, recent major advances in our understanding of the clinical and biologic features of this disease have not been matched by similar advances in treatment. This is likely because of the complex cascade of biologic and pathobiologic events that occurs in IPF. The necessary, and desperately needed, next generation of therapies, focused on specific molecular targets thought to play pivotal roles in the development and progression of fibrosis, are under active investigation.

PMID:
15564021
DOI:
10.1016/j.ccm.2004.08.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center